Hematopoietic growth factors

Ca-A Cancer Journal for Clinicians

Volumn 46, Issue 3, 1996, Pages 165-184

  Bociek, R Gregory ^a   Armitage, J O ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ERYTHROPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM; HODGKIN DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ONCOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 0029941533     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.46.3.165     Document Type: Review

References (138)

1. Clark SC, Kamen R: The human hematopoietic colony-stimulating factors. Science 1987;236:1229-1237.
2. Nicola NA: Hematopoietic cell growth factors and their receptors. Annu Rev Biochem 1989;58:45-77.
3. Emerson SG: The stem cell model of hematopoiesis, in Hoffman R, Benz EJJ, Shattil SJ, et al (eds): Hematology: Basic Principles and Practice. New York, Churchill Livingstone, 1991, pp 72-81.
4. Golde JW, Gasson JC: Hormones that stimulate the growth of blood cells. Sci Am 1988;259:62-71.
5. Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors: Biology and clinical applications. N Engl J Med 1989;321:1449-1459.
6. Metcalf D: The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 1986;67:257-267.
7. Wallerstein RJ, Deisseroth A: Hematopoietic growth factors in cancer treatment. Prin Pract Oncol Update 1990;4:1-16.
8. Weite K, Bonilla MA, Gillio AP, et al: Recombinant human granulocyte colony-stimulating factor: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med 1987;165:941-948.
9. Duhrsen U, Villeval JL, Boyd J, et al: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.
10. Souza LM, Boone TC, Gabrilove J, et al: Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986;232:61-65.
11. Gabrilove JL, Jakubowski A, Fain K, et al: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454-1461.
12. Motoji T, Watanabe M, Uzumaki H, et al: Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br J Haematol 1991; 77:54-59.
13. Wong GG, Witek JS, Temple PA, et al: Human GM-CSF: Molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985;228:810-815.
14. Sieff CA, Niemeyer CM, Mentzer SJ, Faller DV: Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 1988;72:1316-1323.
15. Kaushansky K, Lin N, Adamson JW: Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors: Mechanism for the hematopoietic response to inflammation. J Clin Invest 1988:-81:92-97.
16. Bagby GC Jr, Dinarello CA, Wallace P, et al: Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest 1986;78:1316-1323.
17. Sieff CA, Emerson SG, Donohue RE, et al: Human recombinant granulocyte-macrophage colony-stimulating factor: A multilineage hematopoietin. Science 1985;230:1171-1173.
18. Lopez AF, Williamson DJ, Gamble JR, et al: Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neulrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986;78:1220-1228.
19. Weisbart RH, Golde DW, Clark SC, et al: Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 1985; 314:361-363.
20. Buescher ES, Mcllheran SM, Vadhan-Raj S: Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism. J Infect Dis 1988;158:1140-1142. Letter.
21. Erslev AJ: Humoral regulation of red cell production. Blood 1953;8:349-357.
22. Jacobs K, Shoemaker C, Rudersdorf R, et al: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-810.
23. Lin FK, Suggs S, Lin CH, et al: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985;82:7580-7584.
24. Powell JS, Berkner KL, Lebo RV, Adamson JW: Human erythropoietin gene: High level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci U S A 1986;83:6465-6469.
25. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and phase II clinical trial. N Engl J Med 1987;316:73-78.
26. Winearls CG, Oliver DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-1178.
27. Zanjani ED, Ascensao JL, McGlave PB, et al: Studies on the liver to kidney switch of erythropoietin production. J Clin Invest 1981;67:1183-1188.
28. Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T: Subcutaneous erythropoietin. Lancet 1988;2:406. Letter.
29. Quesenberry PJ, Ihle JN, McGrath E: The effect of interleukin 3 and GM-CSA-2 on megakaryocyte and myeloid clonal colony formation. Blood 1985;65:214-217.
30. Robinson BE, McGrath HE, Quesenberry PJ: Recombinant murine granulocyte-macrophage colony-stimulating factor has megakaryocyte colony-stimulating activity and augments megakaryocyte colony stimulation by interleukin 3. J Clin Invest 1987;79:1648-1652.
31. Ishihashi T, Koziol JA, Burstein SA: Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987;79:286-289.
32. Lok S, Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
33. Kaushansky K, Broudy VC, Grossmann A, et al: Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995;96:1683-1687.
34. Kaushansky K, Lok S, Holly RD, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
35. de Sauvage FJ, Hass PE, Spencer SD, et al: Simulation of megakaryocytopoiesis and thromhopoiesis by the c-Mpl ligand. Nature 1994;369:533-538.
36. Choi ES, Hokom M, Bartley T, et al: Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem Cells 1995;13:317-322.
37. Matsumura I, Kanakura Y, Kato T, et al: Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 1995;86:703-709.
38. Tannock IF, Boyd NF, Deboer G: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-1387.
39. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
40. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BLNI randomised trial. Lancet 1993;341:1051-1054.
41. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259.
42. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
43. Attal M, Harousseau JL, Stoppa AM, et al: High dose therapy in multiple myeloma: Final analysis of a prospective randomized study of the "Intergroupe Francais du Myelome" (IFM90). Blood 1995;86: 124a. Abslract.
44. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995;13:2483-2489.
45. Haioun C, Lepage E, Gisselbrecht C, et al: Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive nonHodgkin's lymphoma (NHL) in first complete remission (CR): A sludy of 542 patients (LNH87-2 protocol). Blood 1995;86:457a. Abstract.
46. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-15.
47. Goldie JH, Coldman AJ: A mathematic model lor relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
48. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose intensity be increased by using granulocyle colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-659.
49. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-344.
50. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22. Proc Am Soc Clin Oncol 1994;13:64. Abstract.
51. Kessinger A, Armitage JO, Landmark JD, et al: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71: 723-727.
52. Pettengell R, Morgenslern GR, Woll PJ, et al: Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993;82:3770-3777.
53. Kessinger A, Vose JM, Bierman PJ, Armitage JO: High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and replapsed lymphoma: An alternative to bone marrow purging. Exp Hematol 1991;19:1013-1016.
54. Gorin NC, Aegerter P, Auvert B, et al: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990;75:1606-1614.
55. Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-1136.
56. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-1143.
57. To LB, Shepperd KM, Haylock DN, et al: Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18:442-447.
58. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989;2:580-585.
59. Elias AD, Ayash L, Anderson KC, et al: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992;79:3036-3044.
60. Sharp JG, Kessinger A, Mann S, et al: Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Clon 1992;10(suppl 1):92-94.
61. Ross AA, Cooper BW, Lazarus HM, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-2610.
62. Moss TJ, Sanders DG, Lasky LC, Bostrom B: Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990;76:1879-1883.
63. Craig JI, Langlands K, Parker AC, Anthony RS: Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994;22:898-902.
64. Henon PR, Liang H, Beck-Wirth G, et al: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9:285-291.
65. Vose JM, Anderson JR, Kessinger A, et al: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11:1846-1851.
66. Elfenbein G, Janssen W, Perkins J, et al: Pace of engraftment following high dose chemotherapy and autologous stem cell rescue depends on stem cell priming regimen. Proc Am Soc Clin Oncol 1994;13:440. Abstract.
67. Brenner MK, Rill DR, Moen RC, et al: Genemarking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-86.
68. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-383.
69. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869-876.
70. Gorin NC, Coiffier B, Hayat M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: A double-blind placebo-controlled trial. Blood 1992;80:1149-1157.
71. Khwaja A, Linch DC, Goldstone AH, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol 1992;82:317-323.
72. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-1778.
73. Stahel RA, Jost LM, Cerny T, et al: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-1938.
74. Powles R, Smith C, Milan S, et al: Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: Double blind, placebo-controlled trial. Lancet 1990;336:1417-1420.
75. De Witte T, Gratwohl A, Van Der Lely N, et al: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992;79:1359-1365.
76. Nemunaitis J, Anasetti C, Storb R, et al: Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992;79:2572-2577.
77. Nemunaitis J, Rosenfeld C, Ash R, et al: Phase III double-blind trial of rhGM-CSF (Sargramostim) following allogeneic bone marrow transplant (BMT). Blood. 1993;82:286a. Abstract.
78. Klumpp TR, Mangan KF, Goldberg SL, et al: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial. J Clin Oncol 1995;13:1323-1327.
79. Spitzer G, Adkins DR, Spencer V, et al: Randomized study of growth factors post-peripheral-blood stem-celi transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661-670.
80. Vey N, Molnar S, Faucher C, et al: Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: Effect on granulocyte recovery. Bone Marrow Transplant 1994;14:779-782.
81. Khwaja A, Mills W, Leveridge K, et al: Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 1993;11:479-482.
82. Schwartzberg L, Birch R, Weaver C, West W: The effect of varying durations of granulocyte colony stimulating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBPC) infusion. Blood 1994;84:91 a. Abstract.
83. To LB, Roberts MM, Haylock DN, et al: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants, and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-284.
84. Haylock DN, To LB, Dowse TL, et al: Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992;80:1405-1412.
85. Srour EF, Brandt JE, Briddell RA, et al: Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood 1993;81:661-669.
86. Iscove NN, Shaw AR, Keller G: Net increase of pluripolential hematopoietic precursors in suspension culture in response to IL-1 and IL-3. J Immunol 1989;142:2332-2337.
87. + cells from patients wilh stage IV breast cancer. Blood 1994;84:3567-3574.
88. Brugger W, Heimfeld S, Berenson RJ, et al: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-287.
89. + cells mediate hematopoietic recovery in cancer patients after high-dose VP-16, ifosfamide, carhoplatin, and epirubicin. Blood 1994;84:395a. Abstract.
90. Holyoake TL, Alcorn MJ, Richmond L, et al: A phase I study to evaluate the safety of re-infusing CD34 cells expanded ex-vivo as part or all of a PBPC transplant procedure. Blood 1995;86:294a. Abstract.
91. Williams SF, Bender JG, Zimmerman T, et al: Selection and expansion of CD34+ cells: Their clinical utility in autologous stem cell reinfusion. Proc Am Soc Clin Oncol 1995;14:328. Abstract.
92. Nemunaitis J, Rosenfeld C, Collins R, et al: Allogeneic transplantation combining mobilized blood and bone marrow in patients with refractory hematologic malignancies. Transfusion 1995;35: 666-673.
93. Korbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995;85:1659-1665.
94. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85:1655-1658.
95. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85: 1666-1672.
96. Dreger P, Haferlach T, Eckstein V, et al: G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safely, kinetics of mobilization, and composition of the graft. Br J Haematol 1994;87:609-613.
97. Oblon DJ, Paul S, Oblon MB, Yankee R: Allogeneic peripheral blood stem cell transplants: Preliminary results. Blood 1994;84:94a. Abstract.
98. Majolino I, Buscemi F, Scime R, et al: G-CSF mobilized PBSC for alloseneic transplantation. Blood 1994;84:92a. Abstract.
99. Majolino I, Saglio G, Scime R, et al: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell (PBSC) transplantation in patients with hematologic malignancies. Blood 1995;86:108a. Abstract.
100. Anderlini P, Przepiorka D, Khouri I, et al: Chronic graft-versus-host disease (GVHD) after allogeneic marrow or blood siem cell transplantation. Blood 1995;86:109a. Abstract.
101. Verdonck LF, van Putten WL, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045-1051.
102. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
103. Griffin JD, Young D, Herrmann F, et al: Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67:1448-1453.
104. Horikoshi A, Sawada S, Endo M, et al: Relationship between responsiveness to colony stimulating factors (CSFs) and surface phenotype of leukemic blasts. Leuk Res 1995;19:195-201.
105. Tafuri A, Hegewisch S, Souza L, Andreeff M: Stimulation of leukemic blast cells in vitro by colony stimulating factors (G-CSF, GM-CSF) and interleukin 3 (IL-3): Evidence of recruitment and increased cell killing with cytosine-arabinoside (Ara-C). Blood 1988:72:105a. Abstract.
106. Cannistra SA, Groshek P, Griffin JD: Granulocyte-macrophage colony-stimulating factor enhances the cylotoxic effects of cytosine-arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989;3:328-334.
107. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte colonystimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2086-2092.
108. Estey E, Thall P, Andreeff M, et al: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-678.
109. Bettelheim P, Valent P, Andreeff M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700-711.
110. Jahns-Streubel G, Reuter C, Unterhalt M, et al: Modulation of proliferative activity and intracellular Ara-C metabolism in AML blasts in vivo by GM-CSF priming. Blood 1995;86:517a. Abstract.
111. Mantovani L, Kampfe D, Lehmann P, et al: Treatment of poor prognosis AML with rhGM-CSF and rhG-CSF for priming, followed by cytarabine plus mitoxanlrone induction therapy: A phase I/II study. Blood 1995;86:769a. Abstract.
112. Lowenberg B, Boogaerts MA, Vellenga E, et al: Various modalities of use of GM-CSF in the treatment of acute myelogenous leukemia (AML): A Hovon-Saak randomized study (Hovon-4A). Blood 1995;86:512a. Abstract.
113. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990;322:1689-1692.
114. Abels RI, Larholt KM, Krantz KD, Bryant EC: Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer, in Murphy MJJ (ed): Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology: Proceedings of the Beijing Symposium. Dayton. Ohio. Alpha Med Press, 1991, pp 121-141.
115. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
116. Barlogie B, Beck T: Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993;11:88-94.
117. Henry D, Keller A, Kugler J, et al: Treatment of anemia in cancer patients on cisplatin containing chemotherapy with recombinant erythropoietin (rHu-EPO). Proc Am Soc Clin Oncol 1990;9:182. Abstract.
118. Welch RS, James RD, Wilkinson PM, et al: Recombinant human erythropoietin and platinum based chemotherapy in metastatic ovarian carcinoma. Proc Am Soc Clin Oncol 1993;12:254. Abstract.
119. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-1422.
120. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-slimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
121. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-324.
122. Silvestri F, Velisig M, Fanin R, et al: Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin's lymphomas. Leuk Lymphoma 1995;16:465-470.
123. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized contolled trial. Blood 1992;80:1430-1436.
124. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
125. Nichols CR, Fox EP, Roth BJ, et al: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte-colony stimulating-factor. J Clin Oncol 1994;12:1245-1250.
126. Maher DW, Lieschke GJ, Green M, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia: A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492-501.
127. Mayordomo JI, Rivera F, Diaz-Puente MT, et al: Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: Results of a randomized trial. Proc Am Soc Clin Oncol 1993;12:437. Abstract.
128. Vellenga E, Uyl-de Groot CA, de Wit R, et al: Randomized placebo controlled study of GM-CSF in patients with febrile neutropenia following chemotherapy. Proc Am Soc Clin Oncol 1995;14: 255. Abstract.
129. Talcott JA, Whalen A, Clark J, et al: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-114.
130. Tomiak AT, Yau JC, Huan SD, et al: Duration of intravenous antibiotics for patients with neutropenic fever. Ann Oncol 1994;5:441-445.
131. Nakajima H, Ikeda Y, Hirashima K, et al: A randomized controlled study of rG.CSF in patients with neutropenia after induction therapy for acute myelogenous leukemia. Rinsho Ketsueki 1995; 36:597-605.
132. Takeshita A, Ohno R, Hirashima K, et al: A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. Rinsho Ketsueki 1995;36:606-614.
133. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
134. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671-1677.
135. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia: AML Cooperative Group study. N Engl J Med 1995;332:1678-1683.
136. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323:871-877.
137. Heil G, Hoelzer D, Sanz MA, et al: Results of a randomised, double-blind, placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with denovo acute myeloid leukaemia. Blood 1995;86:267a. Abstract.
138. Goodwin JE, Kopecky KJ, Head DR, et al: A double-blind placebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1995;86:434a. Abstract.